

D-2875

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-68 (Cancelled).

69. (Currently amended) An agent for treating pain comprising a modified botulinum neurotoxin comprising a botulinum neurotoxin H<sub>B</sub>, a botulinum neurotoxin L chain, and no functional H<sub>C</sub> domain, the modified botulinum neurotoxin being covalently coupled to substance P so that the modified botulinum neurotoxin no longer binds to botulinum neurotoxin receptors at a neuromuscular junction with the same affinity as the native botulinum neurotoxin.

70. (Cancelled)

71. (Currently amended) The agent of claim 69, wherein the botulinum neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

72. (Currently amended) The agent of claim 69, wherein the botulinum neurotoxin is botulinum toxin serotype A.

73. (Currently amended) The agent of claim 69, wherein the agent is a fusion protein.

D-2875

74. (Cancelled)

75. (Currently amended) The agent of claim 69, wherein the L chain is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype [[C1]] C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

76. (Previously presented) The agent of claim 69, wherein the H<sub>N</sub> is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

Claims 77-80 (Cancelled).